30 results
8-K
EX-99.1
DMAC
DiaMedica Therapeutics Inc.
21 Jun 23
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
8:16am
.
“We look forward to re-engaging with our study sites and stroke expert principal investigators as we resume our ReMEDy2 trial as there is continued
424B3
DMAC
DiaMedica Therapeutics Inc.
15 Oct 21
Prospectus supplement
6:32am
biotechnology companies and is a recognized expert in endovascular therapy, thrombolysis, mechanical thrombectomy, and endovascular surgery. He is Chief
8-K
EX-99.1
hvojct
11 Aug 21
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results
4:30pm
10-K/A
5z44lxwxi blpvn
29 Apr 21
Annual report (amended)
4:34pm
424B5
dnyqenoqt
11 Feb 20
Prospectus supplement for primary offering
5:31pm
424B5
q6ibnym2 0jfouhjbw
11 Feb 20
Prospectus supplement for primary offering
7:02am
8-K
EX-10.1
6z3r9psxn5u35 j6p1
4 Jun 19
Entry into a Material Definitive Agreement
7:30am
DEF 14A
67qvo1aej
8 Apr 19
Definitive proxy
6:04am
PRE 14A
6itx12 vhv45
20 Mar 19
Preliminary proxy
4:31pm
424B4
bscdocll j0jhivzfj
10 Dec 18
Prospectus supplement with pricing info
4:50pm
S-1/A
1qb8 aatuhxoj15jt2
19 Nov 18
IPO registration (amended)
5:01pm
S-1
EX-4.2
ymmn3 rss3f
9 Nov 18
IPO registration
4:21pm